TABLE 2.
Baseline demographic and clinical characteristics and 28‐day acyclovir and 9‐CMMG concentrations
| Characteristics | Baseline assessment (n = 33) |
|---|---|
| Age (years), mean ± SD | 74.4 ± 4.3 |
| Sex (women), n (%) | 12 (36.4) |
| APOE genotype | |
| ε2/ε4, n (%) | 2 (6.1) |
| ε3/ε4, n (%) | 24 (72.7) |
| ε4/ε4, n (%) | 7 (21.2) |
| PILRA genotype | |
| AA, n (%) | 5 (15.2) |
| AG, n (%) | 12 (36.4) |
| GG, n (%) | 16 (48.5) |
| GM 3/17 genotype | |
| 3/3, n (%) | 10 (30.3) |
| 3/17, n (%) | 19 (57.6) |
| 17/17, n (%) | 4 (12.1) |
| Serum anti‐HSV‐1 IgG‐positive, n (%) | 31 (93.9) |
| Serum anti‐HSV‐2 IgG‐positive, n (%) | 9 (27.3) |
| Serum anti‐CMV IgG‐positive, n (%) | 27 (81.8) |
| MMSE score, median (IQR) | 23 (19‐26) |
| CSF Aβ42/40 ratio ≤ 0.072, n (%) | 31 (96.9) a |
| 28‐day assessment (n = 33) | |
|---|---|
| Serum acyclovir, μmol/L, mean ± SD | 25.94 ± 14.48 |
| CSF acyclovir, μmol/L, mean ± SD | 5.29 ± 2.31 |
| CSF/serum acyclovir ratio, median (IQR) | 0.20 (0.15–0.32) |
| Serum 9‐CMMG, μmol/L, mean ± SD | 3.86 ± 2.07 |
| CSF 9‐CMMG, μmol/L, median (IQR) | 0.00 (0.00–0.00) b |
| CSF/serum 9‐CMMG ratio, median (IQR) | 0.00 (0.00–0.00) b |
| Time from last valacyclovir dose, min, median (IQR) | 150 (82.5‐240) |
Abbreviations: 9‐CMMG, 9‐carboxymethoxymethylguanine; Aβ, amyloid beta; APOE, apolipoprotein E; CMV, cytomegalovirus; CSF, cerebrospinal fluid; GM, γ marker; HSV, herpes simplex virus; IgG, immunoglobulin G; IQR, interquartile range; MMSE, Mini‐Mental State Examination; PILRA, paired immunoglobulin‐like type 2 receptor alpha; SD, standard deviation.
a
Total n = 32.
b
Only four participants had detectable CSF 9‐CMMG concentrations (0.1640, 0.1706, 0.1930, and 0.4816 μmol/L, respectively), with corresponding CSF/serum 9‐CMMG ratios of 0.0212, 0.0274, 0.0357, and 0.0578, respectively.